Bryan Roberts
Partner @ Venrock
Palo Alto, United States
Bryan Roberts is a Series B investor at Venrock in Palo Alto focused on Health Care and Biotechnology. Bryan E. Roberts is based out of Palo Alto, California and is the Partner of Venrock. Bryan previously worked at The Aspen Institute as a Henry Crown Fellow. Bryan E. Roberts attended Harvard University.
- Total investments:
- 66
- Last investment:
- Lead investor:
- 24%
Last updated:
For AI agents: llms.txt
Industries Bryan Roberts invests in
Stages Bryan Roberts invests in
Countries Bryan Roberts invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 24 (36%)
- Biotechnology 19 (29%)
- Medical 10 (15%)
- Therapeutics 7 (11%)
- Life Science 5 (8%)
Stage
- Series B 15 (23%)
- Series C 14 (21%)
- Seed 9 (14%)
- Series D 9 (14%)
- Series A 8 (12%)
Country
- United States 31 (47%)
- China 1 (2%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Suki is an AI-powered, voice-enabled digital assistant for doctors. It was designed to help healthcare organizations with their administrative tasks. Suki helps physicians in dictating notes, retrieving info, and works with EHR. The company was founded in 2017 and is headquartered in Redwood City, California. | $90M / Series E / Oct 12, 2026 | ||
| Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad range of severe genetic disorders. The company's therapy pipeline addresses devastating genetic and acquired disorders spanning multiple disease pathways including neurocircuitry, metabolic disorders, neurodegeneration and cardiovasculardisease, enabling medical practitioners to treat patients and improve their lives. | $275M / Series F / Sep 09, 2026 | ||
| K2 Therapeutics creates advanced antibody-based therapies focused on difficult multi-pass membrane targets to address unmet disease needs. | Seed / Jan 01, 2025 | ||
| Suki is an AI-powered, voice-enabled digital assistant for doctors. It was designed to help healthcare organizations with their administrative tasks. Suki helps physicians in dictating notes, retrieving info, and works with EHR. The company was founded in 2017 and is headquartered in Redwood City, California. | $70M / Series D / Oct 10, 2024 | ||
| Element Biosciences is a multi-disciplinary startup focused on innovating genetic analysis tools for the research and diagnostic markets. We are developing a modular and high-performing DNA sequencing platform that will deliver high quality data, workflow flexibility, and make next-generation sequencing technology more accessible. Our proprietaryapproach to improve the signal-to-noise ratio allows us to provide groundbreaking innovations in surface chemistry, instrumentation and biochemistry to drastically decrease the run cost and capital cost while delivering high sequencing data quality. | $277M / Series D / Jul 11, 2024 | ||
| SmithRx is a pharmacy benefits partner built on a modern technology platform that creates new levels of flexibility, efficiency, and customer satisfaction. It’s a new path forward that aligns incentives and harnesses data analytics to deliver an exceptional pharmacy benefit product.A San Francisco-based technology company, SmithRx was founded in2016 to create a cost-competitive PBM that offers clients a proven pass-through model, a single technology platform, concierge-level service, and strong drug cost, rebate, and service level guarantees. The in-house team brings together experience from healthcare companies including Anthem, Collective Health, and Castlight Health, as well as a broader set of technology leaders including Facebook, LinkedIn, Glassdoor, and Docker. Front-line clinicians guide plan execution and member support.Named after a smith, a craftsman, or someone who is precise about their trade. SmithRx embodies these characteristics and brings precision to the pharmacy benefits industry by leveraging technology and data to forge the product of the future. | $60M / Series C / Jan 23, 2024 | ||
Moonlight Bio
|
Seed / Jan 01, 2023 | ||
| SmithRx is a pharmacy benefits partner built on a modern technology platform that creates new levels of flexibility, efficiency, and customer satisfaction. It’s a new path forward that aligns incentives and harnesses data analytics to deliver an exceptional pharmacy benefit product.A San Francisco-based technology company, SmithRx was founded in2016 to create a cost-competitive PBM that offers clients a proven pass-through model, a single technology platform, concierge-level service, and strong drug cost, rebate, and service level guarantees. The in-house team brings together experience from healthcare companies including Anthem, Collective Health, and Castlight Health, as well as a broader set of technology leaders including Facebook, LinkedIn, Glassdoor, and Docker. Front-line clinicians guide plan execution and member support.Named after a smith, a craftsman, or someone who is precise about their trade. SmithRx embodies these characteristics and brings precision to the pharmacy benefits industry by leveraging technology and data to forge the product of the future. | $27.2M / Series B / Mar 10, 2022 | ||
| Accompany Health provides comprehensive in-home care to patients who live in sometimes underserved regions. Accompany Health offers primary care services such as chronic illness management and treatment of new symptoms. They also assist in the organization and coordination of care. There will be no more waiting rooms or lines for another form.Accompany Health cultivates long-term connections with the people they serve so that they know, without a doubt, that the team is there for them at all hours of the day and night, year after year. | Seed / Jan 01, 2022 | ||
| Mythic Therapeutics is a biotechnology company focused on a new generation of groundbreaking cancer therapeutics. The company is pioneering a powerful protein engineering-focused approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics. Their technology dramatically increases therapeuticpotency without compromising safety, thereby unlocking the full potential of targeted therapies against a broad array of tumor targets. | $103M / Series B / Dec 15, 2021 | ||
| See all 66 investments → | |||
Co-Investors
About Venrock
Venrock continues a tradition of partnering with entrepreneurs to establish successful, enduring companies. With a primary focus on technology and healthcare, portfolio companies have included Apple Computer, Athenahealth, Centocor, Check Point Software, DoubleClick, Endeca, Gilead Sciences, Idec Pharma, Imperva, Illumina, Intel, Nest, SlideShare, and Tudou.
Venrock Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andrew Gottesdiener
Partner
|
|||
Anthony Evnin
Partner Emeritus
|
|||
|
Bryan Roberts
Partner
|
|||
Mariana Mihalusova
Vice President
|
|||
Mike Tyrrell
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Bryan Roberts invest in?
Bryan Roberts invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 66 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Bryan Roberts?
Public channels for Bryan Roberts include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Bryan Roberts last invest?
The most recent investment recorded for Bryan Roberts closed in Oct 2026. Shizune tracks 66 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
